美洛昔康和萘丁美酮双盲对照治疗骨关节炎的比较

Meloxicam vs nabumetone in treating osteoarthritis: a double-blind, control study

目的 :比较美洛昔康和萘丁美酮治疗骨关节炎的疗效和安全性。方法 :为随机、双盲、多中心、平行对照研究。共完成病例 60例 ,美洛昔康组 31例 (男性 3例 ,女性 2 8例 ,年龄 5 4a±s 8a) ,用美洛昔康 7.5mg ,qd ;萘丁美酮组 2 9例 (男性 5例 ,女性 2 4例 ,年龄 5 5a± 7a) ,用萘丁美酮 10 0 0mg ,qd ,均在晚餐后口服给药 ,疗程 4wk。结果 :美洛昔康组总有效率为 89% ;萘丁美酮组为 83% (P >0 .0 5 )。不良反应发生率 ,美洛昔康组为 13% ;萘丁美酮组为 10 % (P >0 .0 5 ) ,以胃肠道反应为主。结论 :美洛昔康对骨关节炎具有明显抗炎镇痛作用 。

AIM: To compare the therapeutic effects and safety of meloxicam and nabumetone in the treatment of osteoarthritis. METHODS: In the double blind, randomized, paralleled and multicenter studies, thirty one patietns(M 3, F 28;age 54 a± s 8 a) were given meloxicam 7.5 mg po qd for 4 wk and twenty nine patients (M 5, F 24; age 55 a±7 a) were given nabumetone 1 000 mg po qd for 4 wk. RESULTS: Both meloxicam and nabumetone could improve the inflammatory symptoms and signs of patients with total effective rates 89 % and 83 % respectively (P>0.05) and adverse reactions rates of 13 % and 10 % respectively ( P >0.05). CONCLUSION: Meloxicam is effective and safe in the treatment of osteoarthritis, compared with nabumetone without significant difference.